Navigation Links
Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
Date:4/25/2008

A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

In a late-breaking abstract presented at the 1st European Lung Cancer Conference jointly organized by the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO), Prof. Giorgio Scagliotti from the University of Torino, Italy presented data from the clinical trial stopped in February.

For some patients, the drug results in worse outcomes. "Based on a planned interim analysis the study showed a clear inferiority from adding sorafenib to carboplatin/paclitaxel in first-line non-small-cell lung cancer patients with squamous histology," Prof. Scagliotti said.

Sorafenib is an oral multikinase inhibitor with anti-angiogenic and antiproliferative activity. The drug, marketed as Nexavar by Bayer, is already approved for use in more than 40 countries for liver cancer and more than 70 countries for renal cell cancer.

The latest trial included 926 patients with unresectable stage IIIB/IV non-small-cell lung cancer who had received no prior systemic treatment. Patients were randomized to receive carboplatin plus paclitaxel, combined with either sorafenib 400 mg or placebo.

After a formal review of the ongoing study, the trial's data monitoring committee recommended termination. Preliminary results showed a median overall survival of 10.7 months in the sorafenib group vs 10.6 months in the placebo arm. Sorafenib-treated patients with squamous-cell non-small-cell lung cancer had a greater mortality rate than those with non-squamous histology.

"To date there is no evidence of any detrimental effect from sorafenib in ad
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Invention gives improved gene technology analysis
2. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
3. Genome analysis reveals new protein associated with breast cancer progression
4. Analysis Highlights Economic Contribution of Hospitals to Communities
5. SAIC Awarded DIA Intelligence Analysis Contract
6. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
7. New High Performance Gas Chromatographs and Analysis Solutions From Varian, Inc. Offer Enhanced Performance and Capabilities for More Applications
8. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
9. Some Cancer Trials Overstate Findings, Analysis Claims
10. Review of group-based cancer trials reveals flaws in studies design and analysis
11. Stanford University School of Medicine to Address Improving Network Security and Management at EDUCAUSE Western Regional Conference 2008 Using Lancopes StealthWatch System for Network Behavior Analysis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...The following is an investment opinion release iss... Intellivest Securities Research, Inc., ("ISR") a ...ed a Report on BioClinica, Inc. ( BIOC) which serv...and medical device industries. A primary service ...t medical imaging portions of their submissions re...
(Date:11/29/2009)...ads to more self-defensive finger pointing, study ...s) -- The blame game is a contagious one, a new st..., Researchers found that when people see someone b...nfair accusation, they,re much more likely to enga...rs protecting their egos, we become defensive, too...
(Date:11/28/2009)... Welcome to syngo® .plaza(1), the new...om Siemens Healthcare. As the first Picture Ar...emens where 2D, 3D, and 4D reading come together i... the way multimodality images are read today. Siem...entific Assembly and Annual Meeting of the Radiolo...
(Date:11/27/2009)...re-FirstCall/ -- GSI Group Inc. (Pink Sheets: GSIG...ogy products and semiconductor systems, today anno...eholders has been scheduled for Friday, April 30, ...e announced in due course. As previously announce...Stephen Bershad, a holder of greater than ten perc...
(Date:11/27/2009)...re-USNewswire/ -- Preventing disease is the goal o... year, new vaccines are being added to assist in d...ity for the same period of time? And, if not, when...unity strong? ,, In this month,s issue of Ped...diatrics, Michael Pichichero MD, Director of the R...
Breaking Medicine News(10 mins):Health News:Research Report on BioClinica, Inc. as Speculative Buy 2Health News:When Accusations Start to Fly, They Multiply 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3
... Patients with rheumatoid arthritis hopes have bee...howed positive results and was safe without any si... Roche Holding AG will file the drug Actemra for r...4519.TO), which is controlled by Roche. Roche owns...
... Civilians in Indonesia's Aceh, which was wracked ...s of mental trauma that could trigger more violenc...e International Organisation for Migration and Har... 39 percent for anxiety. The report sampl...
... Animal rights activists strutted naked through To... boycott of fashion giant Burberry for using fur....p to the Burberry store on the Ginza strip of high...st by People for the Ethical Treatment of Animals,...
... The many Australians taking to the bottle is not ...ed a bottle neck in the health system, overburdene...n the people’s health. Binge drinking has b...the next 20 years. Many Australians will be suffer...
... One of Australia's biggest bread companies is not...brands of bread with folic acid. They are petition...is proposal. The objective of such a proposa... If you ask Ian Greenshields from Goodman Fiel...
... The suspended West Coast Eagles star Ben Cousins ...rents broke the news in March to confirm// that he...evealed that he was under treatment at an overseas...name of the drug that he had been using. Sub...
Other Medicine News:Health News:New Drug for Rheumatoid Arthritis Looks Promising. 2Health News:Indonesia's Acehnese Suffer High Rates of Mental Trauma 2Health News:Cousins Recovering from His Substance Abuse Problem 2
(Date:11/25/2009)..., , WEST PALM BEACH, Fla., Nov. 25 /PRNe...earing impaired Americans, especially the 27 milli...ays may not be all that happy, says audiologist Ci...of HearUSA (Amex: EAR ), one of America,s largest...tudies have linked hearing loss to stress, frustra...
(Date:11/25/2009)..., , BASKING RIDGE, N.J., Nov. 25 /PRNewsw...ny leading the development of antithrombotic aptam...id Mazzo, PhD, CEO and President, will be presenti...nference at the New York Palace Hotel in New York ...:10pm (EST) on Tuesday, December 1 and will includ...
(Date:11/25/2009)..., , NEW YORK, Nov. 25 /PRNewswire/ -...earch report is available in its catalogue: ,, ...ive ,, http://www.reportlinker.com/p0164330/...e.html ,, Rising incidence of breast cancer in... principal factor influencing growth in the mammog...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8DATATRAK Signs 6 Year Study with New Device Client 5306 1DATATRAK Signs 6 Year Study with New Device Client 5306 2DATATRAK Signs 6 Year Study with New Device Client 5306 3Curemark Announces Senior Executive Promotions 5301 1Curemark Announces Senior Executive Promotions 5301 2Curemark Announces Senior Executive Promotions 5301 3Early Defibrillator After Heart Attack May Not Pay Off 59091 1Early Defibrillator After Heart Attack May Not Pay Off 59091 2Early Defibrillator After Heart Attack May Not Pay Off 59091 3
...tigational regimen yielded nearly double SVR rate ...eneration HCV protease inhibitor SCH 900518 presen...k, April 23 Schering-Plough Corporation (NYSE: ... SPRINT-1 study showed boceprevir, its investigati...nation with peginterferon alfa-2b and ribavirin, s...
... Continuing Education Online Activity and Podcast ...ril 22 Acute lymphoblastic leukemia (ALL) is a co...cant advances in the treatment of pediatric patien...ealthcare professionals who treat adult patients w... the multitude of factors affecting management opt...
Other Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Expert Insights in Acute Lymphoblastic Leukemia: Current Challenges and Future Directions 2
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: